Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

@article{Bergshoeff2005IncreasedDO,
  title={Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.},
  author={Alina S Bergshoeff and Pieter L. A. Fraaij and Jennifer M Ndagijimana and Gwenda Verweel and Nico G. Hartwig and Tim Niehues and Ronald de Groot and David M Burger},
  journal={Journal of acquired immune deficiency syndromes},
  year={2005},
  volume={39 1},
  pages={63-8}
}
BACKGROUND Nucleoside reverse transcriptase inhibitor-sparing regimens have not yet been systematically evaluated in children. The nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz lower plasma levels of protease inhibitors in adults and children. Therefore, coadministration of lopinavir/ritonavir with nevirapine and efavirenz necessitates a 30% increase in the dose of lopinavir/ritonavir in adults. In children, the extent of the pharmacokinetic interaction between… CONTINUE READING